Breaks Categories: News

TuesdayOct 14, 2025 10:15 am

BioMedNewsBreaks – NextPlat Corp (NASDAQ: NXPL, NXPLW) Appoints Amanda L. Ferrio as Chief Financial Officer

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, announced the promotion of Amanda L. Ferrio to Chief Financial Officer, succeeding Cecile Munnik, CPA/CA, following a transition period through the company’s Q3 2025 filing. Ferrio, who has over 15 years of accounting and finance experience, previously served as Vice President of Accounting & Finance at Progressive Care LLC, where she led financial reporting, budgeting, and SEC compliance. CEO David Phipps said her deep operational insight will support NextPlat’s focus on financial performance and sustainable shareholder value. To view…

Continue Reading

MondayOct 13, 2025 11:14 am

BioMedNewsBreaks — MindWalk Holdings Corp. (NASDAQ: HYFT) Announces 2.3 Million Share Repurchase Program

MindWalk Holdings (NASDAQ: HYFT), a bio-native AI company, announced that its Board of Directors has authorized a share repurchase program allowing the company to buy back up to 2.3 million common shares, or approximately 5% of its 46.15 million shares outstanding, over a 12-month period beginning Oct. 15, 2025. CEO Jennifer Bath said the program reflects confidence in MindWalk’s long-term prospects and provides flexibility to repurchase shares when market prices diverge from intrinsic value, with purchases to be funded through existing cash, investments, or future cash flows. To view the full press release, visit https://ibn.fm/VArOF About MindWalk MindWalk is a Bio-Native…

Continue Reading

FridayOct 10, 2025 9:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Partners with Brand Institute to Develop Global Brand Identity for AVERSA FENTANYL

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader in pharmaceutical brand name and identity development, to create the worldwide commercial brand name and visual identity for AVERSA FENTANYL, the company’s lead product utilizing its AVERSA(TM) abuse-deterrent transdermal technology. Designed to deter misuse and reduce accidental opioid exposure, AVERSA FENTANYL could become the world’s first abuse-deterrent opioid patch. Brand Institute, with a 75% share of global drug name approvals and 87% of FDA-approved names in 2024, will lead the initiative alongside its…

Continue Reading

ThursdayOct 09, 2025 11:41 am

BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) Appoints Dr. Joel Gagnier as Chief Science Officer to Advance AI-Driven Health Research

Fifty 1 Labs (OTC: FITY), a cutting-edge innovator at the intersection of artificial intelligence, clinical research, and personalized wellness, announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer. A recognized leader in clinical epidemiology and research methodology, Dr. Gagnier currently serves as Associate Professor in Epidemiology & Biostatistics and Surgery at Western University’s Schulich School of Medicine & Dentistry. His expertise in clinical trial design, bias reduction, and patient-reported outcome measures (PROMs) strengthens Fifty1 AI Labs’ commitment to rigorous, evidence-based research, positioning the company to advance AI-driven solutions in musculoskeletal health, pain management, and…

Continue Reading

ThursdayOct 09, 2025 9:00 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Files Provisional Patent to Strengthen Protection of AVERSA(TM) Abuse-Deterrent Technology

Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal technology. The filing covers improved aversive formulations and coating application methods designed to enhance abuse deterrence and increase resistance to tampering. If converted to a non-provisional patent and granted, the new patent could extend AVERSA’s protection by up to 20 years from the filing date. AVERSA(TM) technology, already patented in 46 countries, incorporates aversive agents into transdermal patches to prevent misuse of drugs with abuse potential while…

Continue Reading

WednesdayOct 08, 2025 1:54 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL, NXPLW) Issues Q4 Shareholder Update Highlighting Cost Reductions, Healthcare Expansion, and Growth Across Core Channels 

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels, issued a shareholder update detailing operational progress and strategic initiatives for the remainder of 2025. Interim CEO Charles M. Fernandez reported that the company has implemented a comprehensive restructuring plan focused on cost reduction, operational efficiency, and growth acceleration. Recent actions include realignment of NextPlat’s healthcare management team under Progressive Care’s new Vice President of Healthcare Operations, Birute Norkute, and the identification of approximately $2 million in annualized expense savings. The company also reported significant progress across its three…

Continue Reading

WednesdayOct 08, 2025 10:35 am

BioMedNewsBreaks — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Highlights Need for Advanced 3D Imaging During Breast Cancer Awareness Month

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company developing imaging-based technologies for more accurate breast cancer screening, diagnosis, and treatment, marked Breast Cancer Awareness Month by emphasizing the limitations of current imaging tools and the significant opportunity for its flagship IzoView Breast CT Imaging System. With more than 2.3 million new breast cancer cases reported globally each year—and over 315,000 expected in the U.S. in 2025—Izotropic underscored the urgent need for true high-resolution 3D imaging, especially for women with dense breast tissue, which affects roughly 50% of women and diminishes the accuracy of compression-based screening. As the…

Continue Reading

WednesdayOct 08, 2025 10:16 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia

Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., announced that Sapu Nano presented its poster, “Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). The study marks the first clinical trial of an intravenous Deciparticle(TM) formulation of everolimus, an mTOR inhibitor used in breast cancer and other malignancies. Conducted in collaboration with SOCRU, Ingenū, and Medicilon, the trial (ACTRN12625001083482) is now enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia. “Sapu-003…

Continue Reading

WednesdayOct 08, 2025 9:55 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference

Nutriband (NASDAQ: NTRB) announced that Chairman Serguei Melnik will present at Noble Capital Markets’ Emerging Growth Virtual Equity Conference on Wednesday, Oct. 8, 2025, at 3 p.m. ET. The presentation will include a fireside Q&A session with questions from the live virtual audience, and registered investors can also schedule one-on-one meetings with Melnik. Interested attendees can register at no cost via the conference’s official site. A video webcast of the presentation will be available on Channelchek, Noble’s investor portal, and archived for 90 days on both Channelchek.com and Nutriband’s website. To view the full press release, visit https://ibn.fm/MQAEm About Nutriband…

Continue Reading

TuesdayOct 07, 2025 12:32 pm

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Reports Positive Safety Review from DMC in Ongoing Phase 3 FLASH2 Study of HyBryte for CTCL 

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing treatments for rare diseases, announced that its Data Monitoring Committee has completed its first review of the confirmatory Phase 3 FLASH2 study of HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma, concluding there are no safety concerns and that the therapy maintains an acceptable safety profile consistent with prior trials. Enrollment is progressing on schedule, with an update expected in Q4 2025 and a blinded interim efficacy analysis planned for 1H 2026. The FLASH2 trial builds on the Company’s earlier statistically significant Phase 3 results and additional supportive studies demonstrating HyBryte’s efficacy and…

Continue Reading